Dipal Doshi
CEO, Director · Entrada Therapeutics, Inc.
Individual
- 2025
- Sep 3, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Dipal Doshi files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kush Parmar - $3.65M in TRDA purchases and sales in the last 12 months
- MPM BioVentures 2014, L.P. - $3.60M in TRDA purchases and sales in the last 12 months
- MPM BIOVENTURES 2018, L.P. - $3.60M in TRDA purchases and sales in the last 12 months
- 5AM Ventures V, L.P. - $3.00M in TRDA purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $1.61M in TRDA purchases and sales in the last 12 months
- Kory James Wentworth - $434K in TRDA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Dipal Doshi?
Dipal Doshi is a corporate insider, tracked as CEO, Director of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Dipal Doshi submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
